Technical Analysis for RPRX - Royalty Pharma plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical RPRX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Oversold Stochastic | Weakness | -1.16% | |
| Narrow Range Bar | Range Contraction | -1.02% | |
| NR7 | Range Contraction | -1.02% | |
| Lower Bollinger Band Walk | Weakness | -1.02% | |
| Oversold Stochastic | Weakness | -1.02% | |
| Stochastic Buy Signal | Bullish | -1.10% | |
| Lower Bollinger Band Walk | Weakness | -1.10% | |
| Lower Bollinger Band Touch | Weakness | -1.10% | |
| Oversold Stochastic | Weakness | -1.10% | |
| Calm After Storm | Range Contraction | 1.18% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Fell Below Previous Day's Low | about 5 hours ago |
| Down 1% | about 5 hours ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/08/2021
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Industry Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products Biopharmaceutical Industry Drug Development Services
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Industry Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products Biopharmaceutical Industry Drug Development Services
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 53.23 |
| 52 Week Low | 34.8 |
| Average Volume | 2,601,496 |
| 200-Day Moving Average | 43.23 |
| 50-Day Moving Average | 38.43 |
| 20-Day Moving Average | 38.19 |
| 10-Day Moving Average | 37.57 |
| Average True Range | 0.96 |
| ADX | 16.47 |
| +DI | 16.05 |
| -DI | 23.90 |
| Chandelier Exit (Long, 3 ATRs) | 37.15 |
| Chandelier Exit (Short, 3 ATRs) | 38.98 |
| Upper Bollinger Bands | 40.13 |
| Lower Bollinger Band | 36.26 |
| Percent B (%b) | 0.23 |
| BandWidth | 10.15 |
| MACD Line | -0.52 |
| MACD Signal Line | -0.37 |
| MACD Histogram | -0.1454 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 37.93 | ||||
| Resistance 3 (R3) | 37.89 | 37.58 | 37.80 | ||
| Resistance 2 (R2) | 37.58 | 37.38 | 37.61 | 37.76 | |
| Resistance 1 (R1) | 37.37 | 37.26 | 37.48 | 37.41 | 37.71 |
| Pivot Point | 37.06 | 37.06 | 37.12 | 37.09 | 37.06 |
| Support 1 (S1) | 36.85 | 36.86 | 36.96 | 36.89 | 36.59 |
| Support 2 (S2) | 36.54 | 36.74 | 36.57 | 36.54 | |
| Support 3 (S3) | 36.33 | 36.54 | 36.50 | ||
| Support 4 (S4) | 36.37 |
